Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
CardioMind was a medical technology company focused on developing minimally invasive interventional devices for the treatment of small-vessel vascular disease. The company's flagship product, the Sparrow Stent System, featured a self-expanding nitinol stent integrated into a 0.014-inch guidewire, allowing for improved access to distal and tortuous anatomy. This low-profile design was intended to reduce the complexity of stenting procedures in coronary and peripheral arteries by eliminating the need for a separate delivery catheter. CardioMind was acquired by Medtronic in 2010 to bolster its interventional cardiology portfolio and expand its offerings for small-vessel treatment.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on CardioMind.